Spero Therapeutics Inc (SPRO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Spero Therapeutics Inc (SPRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8292
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 IV potentiator platform, and SPR720 non-tuberculosis mycobacterium. The company markets its products through third party distributors. Its partners include U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DoD) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Spero is headquartered in Cambridge, Massachusetts, the US.

Spero Therapeutics Inc (SPRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spero Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio 12
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 13
Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 14
Venture Financing 15
Spero Therapeutics Raises USD51.7 Million in Series C Financing 15
Spero Therapeutics Raises USD30 Million in Series B Funding 17
Spero Therapeutics Raises USD30 Million in Extended Series A Financing 19
Spero Therapeutics Secures Venture Funding 21
Spero Therapeutics Raises USD3 Million in Series A Venture Financing 22
Partnerships 23
Spero Therapeutics Enters into Agreement with US Department of Defense 23
Evotec Extends its Agreement with Spero Therapeutics 24
Licensing Agreements 25
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 25
Spero Therapeutics Enters into Licensing Agreement with Promiliad Biopharma 26
Spero Therapeutics Amends Licensing Agreement with Northern Antibiotics 27
Equity Offering 28
Spero Therapeutics Raises USD75 Million in Public Offering of Shares 28
Spero Therapeutics Raises USD77 Million in IPO 30
Spero Therapeutics Inc – Key Competitors 32
Spero Therapeutics Inc – Key Employees 33
Spero Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 09, 2018: Spero Therapeutics announces second quarter 2018 financial results and pipeline overview 35
May 10, 2018: Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update 37
Apr 02, 2018: Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update 39
Dec 14, 2017: Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update 41
Corporate Communications 43
Aug 14, 2018: Spero announces appointment of John C. Pottage, Jr., MD to its board of directors 43
Feb 01, 2018: Spero Announces Appointment of David P. Southwell to its Board of Directors 44
Jan 04, 2018: Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer 45
Sep 06, 2017: Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team 46
May 22, 2017: Spero Therapeutics Appoints Joel Sendek as Chief Financial Officer 47
Government and Public Interest 48
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 48
Product News 49
05/30/2017: Spero Therapeutics Presents New Data on Lead Potentiator Candidate SPR741 at ASM Microbe 2017 49
05/30/2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017 51
05/04/2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis 52
03/30/2017: Spero Therapeutics Receives $6.8 Million Award from CARB-X to Combat Antibiotic-Resistant Bacteria 53
Clinical Trials 54
Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018 54
Oct 03, 2017: Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform 55
Apr 18, 2017: Spero Therapeutics Highlights Potentiator Program Data at the 27th European Congress of Clinical Microbiology and Infectious Diseases 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spero Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spero Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio 12
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 13
Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 14
Spero Therapeutics Raises USD51.7 Million in Series C Financing 15
Spero Therapeutics Raises USD30 Million in Series B Funding 17
Spero Therapeutics Raises USD30 Million in Extended Series A Financing 19
Spero Therapeutics Secures Venture Funding 21
Spero Therapeutics Raises USD3 Million in Series A Venture Financing 22
Spero Therapeutics Enters into Agreement with US Department of Defense 23
Evotec Extends its Agreement with Spero Therapeutics 24
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 25
Spero Therapeutics Enters into Licensing Agreement with Promiliad Biopharma 26
Spero Therapeutics Amends Licensing Agreement with Northern Antibiotics 27
Spero Therapeutics Raises USD75 Million in Public Offering of Shares 28
Spero Therapeutics Raises USD77 Million in IPO 30
Spero Therapeutics Inc, Key Competitors 32
Spero Therapeutics Inc, Key Employees 33
Spero Therapeutics Inc, Other Locations 34
Spero Therapeutics Inc, Subsidiaries 34

List of Figures
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Spero Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Spero Therapeutics Inc (SPRO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tarveda Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tarveda Therapeutics Inc (Tarveda), formerly Blend Therapeutics Inc is a clinical stage biopharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates. The company develops targeted anti-cancer medicines for advancing the treatment for solid tumors. Its pip …
  • Gulfsands Petroleum plc (GPX):企業の財務・戦略的SWOT分析
    Summary Gulfsands Petroleum Plc (Gulfsands) is an oil and gas company that offers exploration, development, and production services. The company carries out acquisition, exploration, develops, and produces oil and natural gas. It holds interests in oil exploration and development projects in the Syr …
  • Avcorp Industries Inc:企業の戦略・SWOT・財務情報
    Avcorp Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Avcorp Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kelly Services, Inc.:企業の戦略・SWOT・財務分析
    Kelly Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kelly Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sinolink Worldwide Holdings Ltd:企業の戦略・SWOT・財務情報
    Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ATCO Power Ltd:企業の戦略的SWOT分析
    ATCO Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhib …
  • Gear Energy Ltd (GXE):石油・ガス:M&Aディール及び事業提携情報
    Summary Gear Energy Ltd (Gear Energy) is an oil and gas company. The company offers services such as exploration, acquisition, development, operations, management, production and development of low risk, low cost, heavy, and light oil and gas resources. It holds interests, owns and operates petroleu …
  • Canadian Overseas Petroleum Ltd (XOP):石油・ガス:M&Aディール及び事業提携情報
    Summary Canadian Overseas Petroleum Ltd (COPL), formerly Velo Energy Inc is an oil and gas company that offers exploration and production of crude oil and natural gas properties. The company operates single well unappraised discoveries in mature basins and bringing them into production. Its projects …
  • Associated Electric Cooperative Inc.:企業の発電所・SWOT分析2018
    Associated Electric Cooperative Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • BP Plc:企業のM&A・事業提携・投資動向
    BP Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BP Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • KGHM Polska Miedz SA:企業の戦略・SWOT・財務情報
    KGHM Polska Miedz SA - Strategy, SWOT and Corporate Finance Report Summary KGHM Polska Miedz SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Veracyte Inc (VCYT):企業の財務・戦略的SWOT分析
    Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products comprise Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It als …
  • NetScout Systems, Inc. (NTCT):企業の財務・戦略的SWOT分析
    NetScout Systems, Inc. (NTCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Smiths Group Plc (SMIN):企業の財務・戦略的SWOT分析
    Smiths Group Plc (SMIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Sysmex Corp (6869):企業の財務・戦略的SWOT分析
    Sysmex Corp (6869) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design’s p …
  • TransDigm Group Incorporated:企業のM&A・事業提携・投資動向
    TransDigm Group Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransDigm Group Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Huneed Technologies:企業の戦略・SWOT・財務分析
    Huneed Technologies - Strategy, SWOT and Corporate Finance Report Summary Huneed Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆